Giulio Giancaspro

Dr. Giulio Giancaspro

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
DBDomenico Bonamonte
Domenico Bonamonte
AMAurora De Marco
Aurora De Marco
Giulia CiccareseGiulia Ciccarese
Giulia Ciccarese
PRPaolo Romita
Paolo Romita
Giulio GiancasproGiulio Giancaspro
Giulio Giancaspro
CFCATERINA FOTI
CATERINA FOTI
Background/Objectives: The correlation between contact allergy (CA), atopic dermatitis (AD) and psoriasis is still debated. Therefore, the present study aims to retrospectively analyze the frequency of contact sensitization among patients with psoriasis and AD compared to controls, in order to further investigate the relationship between CA and the underlying immunological background. Methods: All data concerning patients who underwent patch testing from 2016 to 2022 in the dermatology clinic of a tertiary center in Southern Italy have been retrospectively collected. Only patients who underwent patch testing with the S.I.D.A.PA. standard series have been selected and divided into three groups: AD group, psoriasis group and control group. Acquired data were organized into database and underwent statistical examination. Results: A total of 2287 patients have been enrolled, including 377 AD patients, 127 psoriatic patients and 1783 controls. The most frequent allergens were nickel and balsam of Peru. Methylisothiazolinone (4.2% vs. 2.2%), paraben mix (0.3% vs. 0%) and neomycin (1.3% vs. 0.4%) significantly provided more positive reactions (PSR) in the AD group compared to the control one, and fragrance mix II displayed a higher rate of positivity in the atopic group compared to the psoriatic one (3.2% vs. 0%). Conclusions: Psoriasis turned out to be a possible protective factor for CA (odds ratio = 0.6), while AD seems to facilitate its development (odds ratio: 1.42). The limitations of this study mainly rely upon its retrospective nature which limited the acquisition of clinical relevance for PSR. Further studies are required to better investigate this topic.

Verified
Journal Article
Open access
PDF file
Cinzia RotondoCinzia Rotondo
Cinzia Rotondo
GBGiuseppe Busto
Giuseppe Busto
RBRaffaele Barile
Raffaele Barile
Giulio GiancasproGiulio Giancaspro
Giulio Giancaspro
BCBrunella Capuano
Brunella Capuano
Addolorata CorradoAddolorata Corrado
Addolorata Corrado
In the clinical context of the new medical concept of diseases related to the Major Histocompatibility Complex class I (MHC-I-opathy), contrasting data are available on the possible association among HLA-B*51, Behcet’s disease (BD), and spondyloarthritis (SpA). The aim of this retrospective study on a cohort of HLA-B*51-positive patients who were clinically observed for almost 5 years is primarily to evaluate which classification criteria they satisfy among BD, axial (ax) or peripheral (p) SpA, and psoriatic arthritis (PsA). Furthermore, we characterized the possible impact of different arthritis phenotypes on the most frequent extra-articular clinical manifestations in BD, ax-SpA, p-SpA, and PsA. A comparison with HLA-B*51-negative patients (matched with HLA-B*51-positive patients for age, gender, and diagnosis, by mean propensity score) was also performed to evaluate the true impact on clinical manifestations of HLA-B*51. We conducted a monocentric retrospective study from 2013 to 2025. The inclusion criteria were HLA-B*51 positivity, the availability of the entire MHC-I class test, and rheumatological clinical follow-up of at least 5 years. The exclusion criterion was positivity for clinically important MCH-I loci other than HLA-B*51. A total of 105 patients met the inclusion criteria in an average clinical observation period of 8.4 ± 2.9 years. All patients were Apulian and were HLA-B* 51 positive. During the follow-up, 32 patients (31%) met the BD criteria, 17 (16%) met the PsA criteria, 25 (24%) met the p-SpA criteria, and 13 (12%) met the ax-SpA criteria. Of note, 16% and 34% of BD patients met the ax-SpA and p-SpA ASAS criteria, respectively. Prevalent articular phenotypes in this HLA-B*51 cluster of patients are a polyarticular pattern and enthesis involvement in all disease groups. In BD patients, axial involvement was associated with a significantly higher percentage of neurological manifestations (40% vs. 7%, p = 0.043) and inflammatory bowel disease (IBD) (100% vs. 15%, p = 0.0001), compared to patients with exclusive peripheral joint involvement. This latest data on IBD remains significant, even in comparison with HLA-B*51 negative patients (33%; p = 0.035). In the p-SpA group, a significantly higher rate of uveitis (28%) was observed compared to both ax-SpA with HLA-B*51-positive (0%, p = 0.035) and p-SpA with HLA-B*51-negative patients (4%, p = 0.030). A high percentage of multi-drug failures was highlighted in patients with PsA (60%) and p-SpA (40%). This study provides new data on the association between HLA-B*51 and the onset of BD and/or SpA or PsA, and its possible impact on extra-articular manifestations. We confirm the higher prevalence of the peripheral articular phenotype in BD, but we also highlight a specific association between the rarer axial involvement and gastrointestinal involvement in HLA-B*51 patients. In SpA, the peripheral articular phenotype appears to be associated with a higher occurrence of uveitis in the presence of HLA-B*51.

22 June 2026 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
RBRaffaele Barile
Raffaele Barile
Cinzia RotondoCinzia Rotondo
Cinzia Rotondo
Giulio GiancasproGiulio Giancaspro
Giulio Giancaspro
VRValeria Rella
Valeria Rella
FCFrancesco P. Cantatore
Francesco P. Cantatore
ACAddolorata Corrado
Addolorata Corrado

7 November 2025 in Journal of Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
Giulio GiancasproGiulio Giancaspro
Giulio Giancaspro
Cinzia RotondoCinzia Rotondo
Cinzia Rotondo
RBRaffaele Barile
Raffaele Barile
VRValeria Rella
Valeria Rella
JCJlenia Casciaro
Jlenia Casciaro
Addolorata CorradoAddolorata Corrado
Addolorata Corrado
Giulio Giancaspro, M.D., Cinzia Rotondo, M.D., Raffaele Barile, M.D., Valeria Rella, M.D., Jlenia Casciaro, M.D., Luigi Nardella, M.D., Francesco Paolo Cantatore, M.D., Addolorata Corrado, M.D.. J Rheum Dis -0001;0:232-. https://doi.org/10.4078/jrd.2025.0136

8 November 2025 in Respiratory Medicine
Verified
Journal Article
Closed access
Giulio GiancasproGiulio Giancaspro
Giulio Giancaspro
CRCinzia Rotondo
Cinzia Rotondo
RBRaffaele Barile
Raffaele Barile
VRValeria Rella
Valeria Rella
FCFrancesco Paolo Cantatore
Francesco Paolo Cantatore
Addolorata CorradoAddolorata Corrado
Addolorata Corrado